Recently, Japan's First Sankyo Pharmaceuticals decided to launch a phase II clinical trial called I-SPY2 TRIAL to verify the safety and efficacy of HER3 monoclonal antibody patritumab in breast cancer.
I-SPY 2 TRIAL is a randomized, controlled, multicenter clinical trial designed to rapidly screen and identify new drugs for first-confirmed, locally advanced breast cancer (stage II/III breast cancer). The experimental group for this clinical trial was Patritumab plus Herceptin (HER2 mAb) or docetaxel (chemotherapy), and the control group was standard therapy. The HER2-positive breast cancer patients were randomly assigned to the experimental group or the control group for 12 weeks of treatment followed by surgery.
The sponsors of the clinical trial said that a number of studies have shown that the combination of HER family monoclonal antibodies will be a new approach to breast cancer treatment, and the next clinical trial will validate HER3 monoclonal antibody combined with HER2 monoclonal antibody for breast treatment. The effect of cancer may be effective in treating patients with HER2-positive breast cancer.
About Patritumab
Patritumab is a fully humanized monoclonal antibody that targets HER3. HER3 is a member of the ERBB family and is a receptor tyrosine kinase that is highly expressed or aberrantly activated in many types of tumors. The HER3 receptor usually binds to other receptors of the HER family, such as EGFR or HER2, to form a heterodimer, thereby promoting the proliferation of tumor cells.
HER2 monoclonal antibodies, such as Roche's Herceptin, have been widely used in HER2-positive breast and gastric cancers, but there are also problems with low response rates or resistance, and preclinical studies have shown that HER3 receptors are single. Anti-in combination with other family member inhibitors can have a good therapeutic effect. In addition to the I-SPY 2 clinical trial, patritumab is currently conducting a Phase II clinical trial to evaluate the efficacy of this drug in the treatment of previously untreated recurrent or metastatic head and neck cancer.
Protein: The protein based on a certain indicator negative charge attracts protein cationic, ionizing causes the color change.
Q1. Do you offer customer brand ? A: We have been doing OEM and ODM service for more than 16 years.
Protection of your sales area, ideas of design and all your private
information.
Q2. What certificate do you have ? A: CE, ISO 9001, ISO13485 certificates
Q3. How is your quality? A: Good comments from all over the world, 100% QC testing before delivery.
Q4. Is it OK to print my logo on product? A: Yes. You can make your own design.
Q5: Do you offer samples for the products? A: Yes, we offer samples free charge, but customer need to bear the delivery fee.
Urine Ph Strips,Urine Test Strips Protein,Diastix Reagent Strips For Urinalysis,Electronic Ph Tester For Urine And Saliva
Changchun LYZ Technology Co., Ltd , https://www.lyzstrips.com